Click here to buy the book Version		Click here to buy the Cd-rom Version

FOREWORD

International Congresses on Thrombosis organized under the auspices of the Mediterranean League against Thromboembolic Diseases every two years, have developed their own continuity and tradition along the following lines: they are established and recognized as main scientific events occurring in the “even” years in the field of thrombosis based diseases and blood coagulation disorders; although usually organized in a country of the Mediterranean area, participation and audience is representative of Europe at large, of both Americas, and other overseas countries; they are characterized by a predominant clinical interest focusing on epidemiology, diagnosis, therapy, management and prevention of thromboembolic diseases, not neglecting basic research in thrombosis and haemostasis; due to this clinical imprint, they are largely multidisciplinary and attract virtually all medical specialists including haematologists, internists, cardiologists, neurologists, surgeons, critical care doctors besides blood coagulation and thrombosis experts.
The 18th International Congress on Thrombosis was held in Ljubljana, Slovenia, from June 20 to June 24, 2004. Traditionally, invited plenary and state-of-the-art lectures and lectures in symposia are published in the League’s official joural Pathophysiology of Haemostasis and Thrombosis. Other authors were given the opportunity to contribute, if they decided to do so, to this publication of Medimond – Monduzzi Editore International Proceedings Division. A number of authors has indeed accepted this offer and a publication was produced representative of a considerable part of the Congress.
We wish to thank all authors contribution to this publication thus allowing a more complete documentation of the 18th International Congress on Thrombosis and activities of the Mediterranean League against Thromboembolic Diseases.

Prof. Mojca Stegnar
President of the 18th International Congress on Thrombosis

Prof. Polona Peternel
Vice President

Doc. Matija Kozak
Scientific Secretary

Dr. Mojca Bozič
General Secretary
 

INDEX

Venous Thromboembolism - Clinical Aspects

Evaluation of the Symptoms of Acute Venous Thromboembolism
R.A. Rached, L. Pereira, A. De Piano, C. Cavalheiro Filho, C.M. Cassaro Strunz,
W. Arminio Hueb, L.F. Cardoso, R. Del Valhe, A. Rached, D. Birolini and D. de Alencar Fischer Chamone

Venous Thromboembolism and Spinal Surgery
K. Hitos, M. Dexter, A. Kam, G. Dandie, A. Cree, G. Butler, K. Saker and J. Fletcher
 

Cardiovascular Disease

Soluble Tissue Factor in Plasma from Patients with Acute Myocardial Infarction Is Not Microvesicle- Associated
I. Seljeflot, T. Lyberg and H. Arnesen

Prothrombotic Risk in White Coat Hypertensives
G.D. Theodossiades, G.P. Vyssoulis, E.A. Karpanou, A.J. Zervoudaki, V.H. Tsevrenis,
D.V. Kokkinos and C.I. Stefanadis

Use of Low-molecular-weight Heparin in Early Cardioversion
A. Dokler Glavnik, F. Škrabl Močnik, P. Zohar, M. Bervar, M. Marinšek and R. Gunzek

The Long-Term Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro®)-Coated Stent in Patients with Coronary Artery Disease
W. Kim, M.H. Jeong, Y.J. Hong, S.Y. Lim, J.H. Kim, Y.K. Ahn, J.G. Cho, J.C. Park, D.L. Cho, H. Kim and J.C. Kang

Plasminogen Activator Inhibitor I (PAI-I) –675 5G/4G polymorphism in patients with Coronary Artery Disease
G. Apergis, M. Belia, A. Bratsas, E. Pavlou, S. Brili, A. Gafou, J. Georgopoulos, C. Stefanadis and E. Andrioti

The Long-Term Clinical Outcomes of Platelet Glycoprotein IIb/IIIa Inhibitor Combined with Low Molecular Weight Heparin in Patients with Acute Coronary Syndrome
J.H. Kim, M.H. Jeong, Y.J. Hong, H.W. Park, W. Kim, Y.K. Ahn, J.G. Cho, J.C. Park and J.C. Kang

Anticoagulant Treatment

Anticoagulation in Conventional Versus Transesophageal Echocardiography (TEE) Guided Cardioversion (CV) of Atrial Fibrillation (AF)
A. Dokler Glavnik, P. Zohar, R. Gunzek, M. Bervar, M. Marinšek and F. Škrabl Močnik

Outpatient Tinzaparin Therapy in 102 Patients with Pulmonary Embolism – Final Results
C.-G. Olsson, U. Bitzén, M. Carlsson, K.Ĺ. Jönsson, P. Magnusson, B. Olsson, B. Jonson and M. Bajc

D-dimer Levels in Long Term Anticoagulated Patients
A. Gafou, K. Maragos, V. Tsevrenis, E. Nomikou, M. Bellia, G. Theodosiadis, E. Paulou and E. Andrioti

Cervical Artery Dissection: Long Term Outcome After Anticoagulant Therapy with LMWH As Initial Treatment
R. Quintavalla, E. Paganelli,
C. Pattacini, A. Rossetti, C. Manotti and P. Piazza

Thrombophilia

Prothrombin G20210 Mutation and Association with Severe Life Threatening Thrombosis Among Thrombophilic Patients
M. Bellia, S. Sklavou, G. Theodosiades, A. Gafou, J. Georgopoulos and E. Andrioti

Perinatal and Paediatric Haemostasis

Alterations of Coagulation Pathway Parameters in Children with Acute Lymphoblastic Leukaemia (ALL)
E.S. Hatzipantelis, M. Athanassiou-Metaxa, V. Tzimouli, D. Kleta, N. Gombakis, V. Garipidou, F. Athanasiadou-Piperopoulou, V. Sidi-Fragandrea, H. Tsantali, D.E. Koliouskas and F. Kanakoudi-Tsakalidou

Is Long Term Prophylaxis in Pediatric Stroke Necessary? A Single Center Study
Ö. Ünal, Z. Uysal, G. Öcal, N. Akar and G. Deda

Alterations of Coagulation Pathway Parameters in Children with Sickle Cell Disease (SCD)
E.S. Hatzipantelis, M. Athanassiou-Metaxa, A. Taparkou, D. Kleta, T. Gerotziafa, N. Gombakis, I. Tsatra, A. Koussi, H. Tsantali, V. Garipidou and F. Kanakoudi-Tsakalidou

Methods in Coagulation

Anti-Xa Activity Monitoring of the Synthetic Pentasaccharide Fondaparinux
P. Van Dreden, S. Fontaine and B. Woodhams

A New TAFI Antigen Assay Independent of Polymorphism 325Thr/Ile and147 Ala/Thr
H. Cost, M. Grimaux, M. Grosley and B. Woodhams

Effect of Platelet Factor 4 on Laboratory Tests for the Protein C System
P. Van Dreden, A. Rousseau and B. Woodhams

Other Aspects of Thromboembolism

Coordinated Dysregulation of Cellular Receptors, Proangiogenic Factors and Intracellular Pathways in Acute leukemia
N. Barbarroja, Ch. Lopez-Pedrera, P. Buendía, E. Siendones, M. Capote, C. Montiel-Duarte, G. Dorado, A. Torres and F. Velasco

Phase I Double Blind, Placebo Controlled, Ascending Single Intravenous Dose Study with a Synthetic Direct Thrombin Inhibitor, TGN255
S. Combe, G. Allen and T. Kennedy

Regulation of NFkB Activation in Anti-Phospholipid Syndrome: Involvement of ERK1/2 and p38 MAP Kinase Pathways
P. Buendía, Ch. López-Pedrera, N. Barbarroja, E. Siendones, C. Montiel-Duarte, G. Dorado, M.A. Aguirre, M.J. Cuadrado, A. Torres and F. Velasco

Prolonged Increase of Plasma Vitamin K2 Concentration by Natto (Bacillus subtilis natto) Ingestion
C. Yatagai, Y. Yanagisawa, T. Ohsugi and H. Sumi